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We present a case of Desquamative Interstitial Pneumonitis occurring during treatment with
pegylated Interferon and Ribavirin in a man with HCV infection.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Interferon is the mainstay of hepatitis C virus (HCV)
treatment.1,2 Although numerous side effects have been
reported during treatments with interferon in chronic
hepatitis C infection: fatigue, flu-like symptoms, headache,terstitial Pneumonitis; HCV,
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mputed Thomography; BAL,
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ll rights reserved.anorexia and myalgias. Rare and serious adverse effects
include permanent hearing loss, cardiac arrhythmias,
cardiomyopathy, renal toxicity, bone marrow suppression
and pancreatitis. Pulmonary complications of IFNs are
unusual, and include interstitial pneumonitis, pulmonary
granulomas or a mimic of pulmonary and extra pulmonary
sarcoidosis, pleural effusion and exacerbation of bronchial
asthma and chronic cough.3e5 There is only one case of
desquamative interstitial pneumonia (DIP) and few cases of
sarcoidosis associated with interferon in literature.
Ribavirin enhances the anti-HCV activity of interferon
leading to a higher and sustained virologic response. Riba-
virin alone has never been reported as the cause for
interstitial lung diseases. However, cough, bronchospasm
and dyspnoea can occur during treatments with ribavirin.
We wish to report a case of man with hepatitis C virus
Table 1 Total cell count.
Macrophages 82%
Lymphocytes 15%
Neutrophils 0%
Eosinophils 3%
78 E. Calabro` et al.infection, who developed interstitial lung diseases during
combined treatment with interferon and ribavirin.
Case report
A 50-year old man with chronic hepatitis C infection of
unknown origin was referred for cough, dyspnoea and fever.
He had recently quit smoke and denied any recent
alcohol or drug consumption. He had no known pulmonary
diseases and no history of respiratory infections.
In 1999, a diagnosis of HCV infection was established,
based on routine analysis.
In 2003 the patient was paled on a combination therapy
of pegylated interferon alpha once weekly and ribavirin
800 mg, for persistent inflammatory activity and HCV
infection. After nine months into treatment initiation
patient was referred for cough, dyspnoea and fever. The
antiviral therapy was stopped.
At admission to the hospital in March 2004 a diffuse
reticule-nodular shadow and bilateral interstitial infiltrates
were present on the chest radiograph. Laboratory param-
eters at initial evaluation included: ASAT 118 U/L, ALAT 72
U/L. Pulmonary function tests showed a reduction in total
lung capacity (TLC) and diffusion capacity to 4.67 l and
57 ml/mmHg/min. On High Resolution Computed Tomog-
raphy (HRCT) there was bilateral patchy ground-glass
shadowing, and an increase in density mainly involving the
lower lobes was present. The HRCT also showed reticular
inter and intralobular opacities. No honey-combing was
present (Fig. 1). Fiberoptic bronchoscopy, bronchoalveolar
lavage (BAL) and transbronchial biopsy were performed.
BAL fluid showed numerous acute inflammatory cells and
macrophages (Table 1). The transbronchial lung biopsy in
the left lower lobe showed a desquamative interstitial
pneumonia, and this confirmed by a video-assisted lung
biopsy from the right lower lobe (Figs. 2 and 3). There was
no evidence for interstitial fibrosis or granulomas.
The patient was started on prednisone 50 mg daily and the
steroid dose was gradually tapered over 6 weeks until the last
follow-up. After treatment with corticosteroid, chest HRCT
findings and pulmonary function tests improved remarkably.Figure 1 High-resolution CT scan of the upper lobes
demonstrates ground-glass attenuation area.Discussion
Recently, several randomized controlled studies have shown
that combination of ribavirin and IFN in chronic hepatitis C
treatment is associated with significantly improved
biochemical and virological response rates comparedwith IFN
alone. Common side effects of interferon therapy include
fatigue, flu-like symptoms, gastrointestinal disturbances, and
neuropsychiatric symptoms, such as impaired memory,
inability to concentrate, and confusion. Other less commonly
described side effects are reversible alopecia, skin rashes,
and thyroid dysfunction. Most of these side effects are asso-
ciated with higher doses. The major side effects of ribavirin
are dose-dependent haemolytic anaemia, cough, dyspnoea,
rash, depression, and dyspepsia. No cases of interstitial
pneumonitis caused by this drug have yet been described.
Combination therapy augments the non-specific immune
response. However, whether ribavirin was a synergistic cause
of the development of interstitial pnemonitis in this patient
remains theoretical. Published case reports of interferon and
ribavirin related pulmonary toxicity during therapy for
chronic hepatitis C are of interstitial pneumonitis, Bronchio-
litis Obliterans Organizing Pneumonia (BOOP), pulmonary
sarcoidosis, pleural effusion and exacerbation of asthma.3e5
Our case represent one of the first cases of DIP reported
in the literature with combinated therapy. The toxicity
occur within the first several weeks of therapy and the
cases reported in literature were reversible in many
instances simply by discontinuation of therapy.
It is possible that pulmonary toxicity after interferon and
ribavirin therapy is more present than previously reported.
A prompt investigation and interruption of therapy, if anyFigure 2 High-resolution CT scan demonstrates a mosaic
pattern of lung attenuation; the abnormal regions are man-
ifested as ground-glass attenuation (arrows).
Figure 3 Alveolar spaces are filled by macrophages with
brown stained cytoplasm. Interalveolar septa are only slightly
thickened (H&E, mid power).
DIP during Interferon and Ribavirin therapy 79sign of significant pulmonary involvement develop, are
recommend.
Conclusion
In summary, the present case suggests that this diagnosis
should be considered in patients on combination therapywho develop respiratory complaints. Until the mechanism
for this effect is better understood and the roles of IFN-a
and ribavirin determined, at present the most prudent
course of action under these circumstances may be to stop
both therapies.
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